ASH® 2025 Highlights: Presenter Vignette – Mark Levis
Dr. Mark Levis
MD, PhD
Johns Hopkins University
1058
Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib
This program has been made possible through unrestricted support from Astellas, Daiichi Sankyo, Eli Lilly and Merck.